Click on the "blue words" above to follow more exciting content.
Today, Medtronic Cardiac Ablation Solutions (CAS) Business Operations Department and Shenzhen CARDIOACC Technology Co., Ltd. officially signed a strategic cooperation agreement at the 8th China International Import Expo (CIIE). The two parties focused on CARDIOACC's independently developedCommercialization and Therapy Promotion of Intracardiac Echocardiography Catheters (hereinafter referred to as "ICE") in ChinaLaunch Long-Term Strategic Cooperation to Jointly Promote the Popularization of ICE-Guided Green Electrophysiology Ablation Therapy. Recently, Medtronic also completed a strategic investment in CARDIOACC, forming a multi-level strategic cooperation between the two parties.Yuansheng Venture Capital exclusively invested in the angel round of CARDIOACC in June 2022.Innovative Therapy ICE —— Driving the New Future of Precision Intervention with "Visualization"ICE (Intracardiac Echocardiography) is an innovative technology in the field of cardiovascular intervention.By inserting a catheter integrated with a miniature ultrasound probe through the femoral artery into the heart chamber, high-definition and dynamic cardiac anatomical images are generated in real time, accurately displaying the heart chamber structure, lesion location, and adjacent relationships.Compared with traditional X-ray imaging, ICE is green and radiation-free, better displays myocardial soft tissue structures, and reduces the need for intraoperative anesthesia. It provides precise navigation and real-time monitoring throughout various minimally invasive cardiac interventional procedures, allowing operators to "see more clearly and perform more steadily" during operations. This innovative technology not only significantly improves the success rate of surgeries and shortens operation time but also effectively reduces the risk of postoperative complications and improves patients' long-term prognosis, bringing good news to cardiovascular disease patients and leading cardiac interventional surgery into a new era of precision treatment.Independent Innovation——China-Made ICE ProductsCARDIOACC's self-developed AgileView intracardiac echocardiography imaging catheter was approved for Class III medical device registration in China in March 2025 (Registration No.: Z20253060489).The catheter has a diameter of only 7.5F.、It can enter the left heart system through the atrial septal puncture sheath with zero difficulty, offering excellent accessibility and flexible control. The product features an innovative self-locking handle design that enables one-handed bending adjustment and zero-position indication, significantly enhancing the convenience and efficiency of intraoperative operation. Meanwhile, AgileView provides clear images with high resolution, andExclusive optimization for PFA (Pulsed Field Ablation) has been performed, enhancing bubble display and catheter contact performance, allowing operators to observe the energy delivery process more clearly and achieve truly visualized precision ablation.
Moving Forward Together——Creating an Integrated Electrophysiology SolutionBoth parties share common expertise in disease areas and a common medical mission.CARDIOACC, focusing on innovative cardiac imaging technology; Medtronic, with its comprehensive training system and therapy ecosystem, jointly making efforts.Through this strategic cooperation, the two parties will realize the deep integration of high-definition imaging and precise ablation technology during surgery, providing doctors with a safer and more efficient surgical experience and offering patients a more reassuring treatment process. Recently, Medtronic also completed a strategic investment in CARDIOACC, forming a multi-level strategic partnership between the two parties.
(Signing Ceremony:In the photo, the guests in the front row from left to right are Mr. Adam Wang from Medtronic and Mr. Xinhuan Zhou from CARDIOACC; in the back row from left to right are Mr. Peitao Zhang from Medtronic, Mr. Song Lin, Mr. Tim Laske, Mr. Yushao Gu, and Rebecca.Mr. Ma Jun, Ms. Feng Wenhui, Ms. Ren Shuman, and Mr. Lin Wei from CARDIOACC.）(At the launch ceremony: In the front row of the photo from left to right are Mr. Fu Cong, Mr. Zhang Peitao, Mr. Lin Song, Ms. Zhang Lei, Ms. Song Jingwei, Ms. Cao Shan, Mr. Laske Tim, Mr. Gu Yushao, Ms. Rebecca, Mr. Adam Wang, Mr. Zhou Xinhuan, Mr. Tarakji Khaldoun, Mr. Ma Jun, Mr. Wang Jinghua, Ms. Zhong Min, Mr. Zhou Quan, Ms. Wang Rong, Ms. Feng Wenhui, Mr. Lin Wei, and Ms. Ren Shuman.)Rebecca Seidel, President of Medtronic's Cardiac Ablation Solutions Division: Medtronic has always believed that technological innovation can transform the treatment landscape. Our collaboration with CARDIOACC is an important step in promoting local innovation and achieving global resource sharing. We look forward to expanding the adoption of ICE therapy, allowing more Chinese patients to benefit from precise visualization interventional technology.
Mr. Gu Yushao, Senior Vice President of Medtronic Global and President of Greater China: Localization innovation has never been a "solo performance," but an endeavor that cannot succeed without an open and win-win cooperative ecosystem. It is a "symphony" that moves with the times, embraces innovation, and achieves mutual success with partners. Over the years, Medtronic has remained committed to deeply connecting with local innovative forces through diversified models such as commercial collaboration, joint research and development, and strategic investment, effectively integrating global technologies with actual needs in China.
Mr. Zhou Xinhuan, CEO of Shenzhen CARDIOACC Technology Co., Ltd.: This collaboration marks an important leap for domestically produced ICE products from research and development to application, offering new possibilities for electrophysiology procedures in China and even globally. CARDIOACC will uphold the principle of "Innovation-driven, patient-first" and advance alongside Medtronic to promote the accessibility and optimization of eco-friendly and precise electrophysiology surgeries.
Mr. Ma Jun, Chief Operating Officer of Shenzhen CARDIOACC Technology Co., Ltd.: Being able to achieve cooperation through Medtronic's rigorous selection process is both a grateful acknowledgment and an invaluable opportunity for our company to refine its innovation, quality, and execution capabilities. We are honored to join hands with an industry leader, and moving forward, we will take this signing as a starting point to deepen collaboration across multiple fields, advance technology in a pragmatic manner, contribute to the progress of medical technology, and ultimately benefit patients.
Mr. Lin Song, Vice President of Medtronic's Cardiac Rhythm, Cardiac Surgery, and Cardiac Ablation Business Team in China, and Head of the Shared Functional Department for Medtronic’s Cardiovascular Business Portfolio in China: Today’s signing is just the beginning. In the future, we will work hand in hand with CARDIOACC to make high-quality medical innovations benefit more patients and turn intracardiac ultrasound tools, which provide clear images and reduce radiation, into reliable assistants for clinicians.Thank you to both teams for their mutual efforts. We look forward to joining hands and creating more possibilities together.
Founded in October 2021, CARDIOACC is dedicated to the research and development of innovative medical devices for cardiac interventional imaging, striving to create high-end medical imaging products with global competitiveness. CARDIOACC has established a robust technological barrier through numerous domestic and international patents. The company leads the industry with several imaging metrics in its 2D intracardiac echocardiography (ICE). Additionally, the 4D ICE system independently developed by CARDIOACC adopts a volumetric scanning imaging solution based on soft beam synthesis, eliminating the need for massive array elements and complex ASIC chips while offering a large field of view and high volume rate, achieving real-time 3D imaging without compromising image quality.
Yuansheng Venture CapitalIt is an investment institution focused on the early and growth-stage healthcare sector, based in Suzhou BioBAY with a global reach. To date, it has completed investments in over 200 outstanding companies in the life sciences and health field, covering four major areas: novel drug development, medical devices, in vitro diagnostics and precision medicine, as well as future medical technologies. These investments have yielded substantial returns, with 20 of these companies already listed on capital markets such as the Hong Kong Stock Exchange and the STAR Market. OrbiMed China has been repeatedly ranked among the top 10 venture capital funds in China's healthcare sector and recognized as one of the most active healthcare investment institutions in China. With a team of seasoned professional investors and a world-class scientific advisory board, OrbiMed China boasts extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry. Leveraging professionalism, focus, and abundant industry resources, we are committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.
